1-6 of 439 Activities
In this CME Outfitters live webcast, expert faculty will guide learners through the burden of cUTI on individual patients and the broader healthcare system, identify opportunities for improved care and outcomes for patients with cUTI through the utilization of up-to-date guidelines and new and emerging antibiotic therapies, and help ensure that patients with cUTI are treated in the appropriate healthcare setting and are transitioned seamlessly between inpatient and outpatient care.
In this CME Outfitters live Q&A, expert faculty will answer questions about the multifaceted impact of GLP-1 RA therapies on glycemic control, CV health, weight management, renal health, liver health, and overall T2D complication risk.
This fast-paced and highly interactive livestream CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply the latest IL-23 inhibitor data, enhance communication and shared decision-making, and deliver truly patient-centered IBD care.
This CME Outfitters Snack activity is the first in the four-part series Linking Knowledge to Action: Empowering HCPs in Screening and Treatment of Patients Across the Viral Hepatitis Spectrum. The series is led by moderators Su Wang, MD (USA) and Heiner Wedemeyer, MD (Germany), with expert discussants Jean-Michel Pawlotsky, MD, PhD (France), Maria Buti, MD, PhD (Spain), George Lau, MD (Hong Kong) and Debika Bhattacharya, MD (USA).
In this CME Outfitters Snack, expert faculty will assess the various presentations of PI, including atypical presentations, to improve PI recognition and diagnosis. Faculty will differentiate among the immunoglobulin therapies available for the treatment of PI that enable optimal, personalized care as well as demonstrate how to develop multidisciplinary, team-based strategies to address disparities in care among patients with PI.
This fourth Snack in the series features experts Naim Alkhouri, MD, and Monica Tincopa, MD, MSc, who together provide practical insights and forward-looking perspectives on where MASH management is headed and what to anticipate in clinical practice.
Primary Immunodeficiency (PI) disorders are a group of more than 180 inherited disorders, of the approximately 550 inborn errors of immunity (IEIs), that predispose affected patients to a variety of bacterial, viral, and fungal infections. Infections may be more prolonged or severe in patients with PI when compared with immunocompetent patients infected with the same organisms.1,2 Early detection of PI and appropriate short- and long-term management of patients with these conditions have been shown to significantly reduce morbidity and mortality.3,4 However, on average it takes 9-15 years to achieve a diagnosis. Pediatric clinicians should be familiar with the history and clinical characteristics that indicate a potential PI and warrant an initial evaluation and/or a referral to an immunologist for evaluation.
It is estimated that between one in 500 to one in 1,200 people in the United States have a PI, amounting to approximately 250,000 cases.5,6 However, there may be as many as 500,000 undiagnosed additional cases, as evidence suggests that these diagnoses often go unrecognized.7
